Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive trial
Ionis announced that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results. IONIS-FXI-LRx is an antisense medicine being developed to treat patients with clotting disorders. October 09, 2019